Healthcare -
Drug Manufacturers - General - NYSE - US
$ 22.785
-4.15 %
$ 129 B
Market Cap
16.58
P/E
1. INTRINSIC VALUE
Balance Sheet
Pfizer Inc.
| Current Assets | 50.4 B |
| Cash & Short-Term Investments | 20.5 B |
| Receivables | 14.8 B |
| Other Current Assets | 15.1 B |
| Non-Current Assets | 163 B |
| Long-Term Investments | 2.23 B |
| PP&E | 18.4 B |
| Other Non-Current Assets | 142 B |
| Current Liabilities | 43 B |
| Accounts Payable | 5.63 B |
| Short-Term Debt | 6.95 B |
| Other Current Liabilities | 30.4 B |
| Non-Current Liabilities | 81.9 B |
| Long-Term Debt | 56.7 B |
| Other Non-Current Liabilities | 25.2 B |
EFFICIENCY
Earnings Waterfall
Pfizer Inc.
| Revenue | 63.6 B |
| Cost Of Revenue | 16.4 B |
| Gross Profit | 47.2 B |
| Operating Expenses | 25.6 B |
| Operating Income | 14.9 B |
| Other Expenses | 6.89 B |
| Net Income | 8.05 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Pfizer Inc.
| Net Income | 8.05 B |
| Depreciation & Amortization | 7.01 B |
| Capital Expenditures | -2.91 B |
| Stock-Based Compensation | 877 M |
| Change in Working Capital | -3.07 B |
| Others | 891 M |
| Free Cash Flow | 9.84 B |
Wall Street Analysts Price Targets
Pfizer Inc.
Wall Street analysts predict an average 1-year price target for PFE of $32.1 , with forecasts ranging from
a
low of
$24 to a high of $36 .
PFE Lowest Price Target
Wall Street Target
24 USD
5.33%
PFE Average Price Target
Wall Street Target
32.1 USD
40.84%
PFE Highest Price Target
Wall Street Target
36 USD
58.00%
4. DIVIDEND
ANALYSIS
1.70%
DIVIDEND YIELD
0.43 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Pfizer Inc.
Sold
0-3 MONTHS
64.8 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
148 K USD 1
Bought
0 USD 0
0-3 MONTHS
499 K USD 1
3-6 MONTHS
28.2 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
New vaccine chief rocks pharmaceutical stocks
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
youtube.com
- 1 week ago
Build A 12%+ Yield On Cost By 2035 With May's Top 10 High-Yield Picks
In this article, I present 10 attractive high-yield investment options for this month of May 2025, which not only offer dividend income but also potential for dividend growth. The selection process involves analyzing financial ratios, competitive advantages, valuations, and diversification across industries and countries to minimize risks and maximize returns. Highlighted top picks for May 2025 include VICI Properties, Chevron, Canadian Natural Resources, Pfizer, Altria, CVS Health, Toronto-Dominion Bank, Comcast, Vale, and Ares Capital.
seekingalpha.com
- 1 week ago
Pfizer Has Unreasonable Whiff Of The Marlboro Man
What makes Pfizer and Altria alike? They have trouble keeping their customers. Altria's dividend yield is 7%, even as it trades at 11 times estimated earnings over the next 12 months – a 40% premium to Pfizer. Pfizer, meanwhile, continues to provide life-saving treatments, while its dealmaking at least offers hope of future breakthroughs.
seekingalpha.com
- 1 week ago
Trump signs order to boost domestic drug manufacturing as pharma tariff threat looms
President Donald Trump signed an executive order to incentivize drug manufacturing in the U.S. The order comes ahead of Trump's planned tariffs on pharmaceuticals imported into the U.S.
cnbc.com
- 2 weeks ago
3 Dividend Stocks Under $100 To Buy This May
With volatility taking center stage since the beginning of the year, investing in the stock market isn't as easy as it was.
247wallst.com
- 2 weeks ago
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
zacks.com
- 2 weeks ago
Top Wide-Moat Stocks to Invest in for Long-Term Growth
Investing in wide-moat stocks like PFE, ASML, LRCX and KO can be a strategy for long-term wealth creation due to their ability to deliver consistent returns.
zacks.com
- 2 weeks ago
Pfizer Stock Up 5% Following Q1 Results: Time to Buy, Sell or Hold?
Investors may stay invested in PFE stock to see how its new growth drivers perform.
zacks.com
- 2 weeks ago
2 Wonderful Dividends At Bargain Basement Prices
Market pessimism creates opportunity. Pfizer and Rexford Industrial trade at historically low valuations, offering high dividend yields and strong long-term growth potential. Pfizer's diversified drug portfolio and promising oncology pipeline support its 7.1% yield and undervalued stock price. Rexford's focus on infill industrial properties in Southern California ensures steady growth. It's supported by a 5% yield and solid financials.
seekingalpha.com
- 2 weeks ago
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 9% (May 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields about 3.74%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 9%.
seekingalpha.com
- 2 weeks ago
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (May 2025)
Shares of Pfizer ( NYSE: PFE ) fell by 2.09% over the past month, compounding the stock's year-to-date troubles that have seen a slide of 9.11%.
247wallst.com
- 2 weeks ago
Build Your Own ATM: 2 Undervalued Dividend Machines Yielding 7%
Predicting markets is nearly impossible, even with perfect foresight; reactions can defy logic. That's why I focus on strategy, not headlines. Recessions are often declared late. By then, stocks may already be up. I prefer acting in fear, not waiting for official confirmation. Instead of chasing safety or volatility, I've picked two stocks that offer reliable income, strong business models, and long-term potential.
seekingalpha.com
- 2 weeks ago
8. Profile
Summary
Pfizer Inc. PFE
COUNTRY
US
INDUSTRY
Drug Manufacturers - General
MARKET CAP
$ 129 B
Dividend Yield
1.70%
Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Contact
235 East 42nd Street, New York, NY, 10017
https://www.pfizer.com
IPO
Date
June 1, 1972
Employees
81000
Officers
Dr. Chris Boshoff FMedSci, M.D., Ph.D.
Chief Scientific Officer and President of Research & Development
Mr. Douglas M. Lankler
Executive Vice President & Chief Legal Officer
Dr. Albert Bourla D.V.M., Ph.D.
Chairman of the Board & Chief Executive Officer
Ms. Jennifer B. Damico
Senior Vice President, Controller & Principal Accounting Officer
Dr. Michael S. Vincent M.D., Ph.D.
Senior Vice President and Chief Scientific Officer of Inflammation & Immunology
Ms. Payal Sahni Becher
Chief People Experience Officer & Executive Vice President
Ms. Sally M. Susman
Executive Vice President & Chief Corporate Affairs Officer
Ms. Lidia L. Fonseca
Executive Vice President and Chief Digital & Technology Officer
Ms. Francesca M. DeMartino
Chief Investor Relations Officer
Mr. David M. Denton
Chief Financial Officer & Executive Vice President